{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T21:34:26Z","timestamp":1774301666218,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,1,14]],"date-time":"2023-01-14T00:00:00Z","timestamp":1673654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,14]],"date-time":"2023-01-14T00:00:00Z","timestamp":1673654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"a Grant-in-Aid for Early-Career Scientists from the Japanese Society for the Promotion of Science KAKENHI","award":["22K16051"],"award-info":[{"award-number":["22K16051"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s00520-023-07576-y","type":"journal-article","created":{"date-parts":[[2023,1,14]],"date-time":"2023-01-14T12:02:32Z","timestamp":1673697752000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Predictors of response to anamorelin in gastrointestinal cancer patients with cachexia: a retrospective study"],"prefix":"10.1007","volume":"31","author":[{"given":"Naoto","family":"Iwai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohei","family":"Oka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Sakagami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Okuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chie","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tasuku","family":"Hara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshifumi","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyuki","family":"Komaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keizo","family":"Kagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshifumi","family":"Doi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshito","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,1,14]]},"reference":[{"key":"7576_CR1","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/s1470-2045(10)70218-7","volume":"12","author":"K Fearon","year":"2011","unstructured":"Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, Davis M, Muscaritoli M, Ottery F, Radbruch L, Ravasco P, Walsh D, Wilcock A, Kaasa S, Baracos VE (2011) Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 12:489\u2013495. https:\/\/doi.org\/10.1016\/s1470-2045(10)70218-7","journal-title":"Lancet Oncol"},{"key":"7576_CR2","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/nrclinonc.2012.209","volume":"10","author":"K Fearon","year":"2013","unstructured":"Fearon K, Arends J, Baracos V (2013) Understanding the mechanisms and treatment options in cancer cachexia. Nat Rev Clin Oncol 10:90\u201399. https:\/\/doi.org\/10.1038\/nrclinonc.2012.209","journal-title":"Nat Rev Clin Oncol"},{"key":"7576_CR3","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1038\/nrc3829","volume":"14","author":"JM Argil\u00e9s","year":"2014","unstructured":"Argil\u00e9s JM, Busquets S, Stemmler B, L\u00f3pez-Soriano FJ (2014) Cancer cachexia: understanding the molecular basis. Nat Rev Cancer 14:754\u2013762. https:\/\/doi.org\/10.1038\/nrc3829","journal-title":"Nat Rev Cancer"},{"key":"7576_CR4","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1080\/01635581.2015.1073753","volume":"67","author":"L Sun","year":"2015","unstructured":"Sun L, Quan XQ, Yu S (2015) An epidemiological survey of cachexia in advanced cancer patients and analysis on its diagnostic and treatment status. Nutr Cancer 67:1056\u20131062. https:\/\/doi.org\/10.1080\/01635581.2015.1073753","journal-title":"Nutr Cancer"},{"key":"7576_CR5","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1200\/jco.2012.45.2722","volume":"31","author":"L Martin","year":"2013","unstructured":"Martin L, Birdsell L, Macdonald N, Reiman T, Clandinin MT, McCargar LJ, Murphy R, Ghosh S, Sawyer MB, Baracos VE (2013) Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol 31:1539\u20131547. https:\/\/doi.org\/10.1200\/jco.2012.45.2722","journal-title":"J Clin Oncol"},{"key":"7576_CR6","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1200\/jco.2014.56.1894","volume":"33","author":"L Martin","year":"2015","unstructured":"Martin L, Senesse P, Gioulbasanis I, Antoun S, Bozzetti F, Deans C, Strasser F, Thoresen L, Jagoe RT, Chasen M, Lundholm K, Bosaeus I, Fearon KH, Baracos VE (2015) Diagnostic criteria for the classification of cancer-associated weight loss. J Clin Oncol 33:90\u201399. https:\/\/doi.org\/10.1200\/jco.2014.56.1894","journal-title":"J Clin Oncol"},{"key":"7576_CR7","doi-asserted-by":"publisher","first-page":"5859","DOI":"10.21873\/anticanres.12928","volume":"38","author":"K Sugiyama","year":"2018","unstructured":"Sugiyama K, Narita Y, Mitani S, Honda K, Masuishi T, Taniguchi H, Kadowaki S, Ura T, Ando M, Tajika M, Muro K (2018) Baseline sarcopenia and skeletal muscle loss during chemotherapy affect survival outcomes in metastatic gastric cancer. Anticancer Res 38:5859\u20135866. https:\/\/doi.org\/10.21873\/anticanres.12928","journal-title":"Anticancer Res"},{"key":"7576_CR8","doi-asserted-by":"publisher","unstructured":"Iwai N, Okuda T, Oka K, Sakagami J, Harada T, Ohara T, Hattori C, Taniguchi M, Sakai H, Hara T, Tsuji T, Komaki T, Kagawa K, Dohi O, Yasuda H, Itoh Y (2021) Depletion of psoas muscle mass after systemic chemotherapy is associated with poor prognosis in patients with unresectable pancreatic cancer. Cancers (Basel) 13. https:\/\/doi.org\/10.3390\/cancers13153860","DOI":"10.3390\/cancers13153860"},{"key":"7576_CR9","doi-asserted-by":"publisher","first-page":"e0129742","DOI":"10.1371\/journal.pone.0129742","volume":"10","author":"Y Miyamoto","year":"2015","unstructured":"Miyamoto Y, Baba Y, Sakamoto Y, Ohuchi M, Tokunaga R, Kurashige J, Hiyoshi Y, Iwagami S, Yoshida N, Watanabe M, Baba H (2015) negative impact of skeletal muscle loss after systemic chemotherapy in patients with unresectable colorectal cancer. PLoS One 10:e0129742. https:\/\/doi.org\/10.1371\/journal.pone.0129742","journal-title":"PLoS One"},{"key":"7576_CR10","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/s1470-2045(15)00558-6","volume":"17","author":"JS Temel","year":"2016","unstructured":"Temel JS, Abernethy AP, Currow DC, Friend J, Duus EM, Yan Y, Fearon KC (2016) Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. Lancet Oncol 17:519\u2013531. https:\/\/doi.org\/10.1016\/s1470-2045(15)00558-6","journal-title":"Lancet Oncol"},{"key":"7576_CR11","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1093\/annonc\/mdx192","volume":"28","author":"D Currow","year":"2017","unstructured":"Currow D, Temel JS, Abernethy A, Milanowski J, Friend J, Fearon KC (2017) ROMANA 3: a phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia. Ann Oncol 28:1949\u20131956. https:\/\/doi.org\/10.1093\/annonc\/mdx192","journal-title":"Ann Oncol"},{"key":"7576_CR12","doi-asserted-by":"publisher","first-page":"3495","DOI":"10.1007\/s00520-016-3144-z","volume":"24","author":"K Takayama","year":"2016","unstructured":"Takayama K, Katakami N, Yokoyama T, Atagi S, Yoshimori K, Kagamu H, Saito H, Takiguchi Y, Aoe K, Koyama A, Komura N, Eguchi K (2016) Anamorelin (ONO-7643) in Japanese patients with non-small cell lung cancer and cachexia: results of a randomized phase 2 trial. Support Care Cancer 24:3495\u20133505. https:\/\/doi.org\/10.1007\/s00520-016-3144-z","journal-title":"Support Care Cancer"},{"key":"7576_CR13","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1002\/cncr.31128","volume":"124","author":"N Katakami","year":"2018","unstructured":"Katakami N, Uchino J, Yokoyama T, Naito T, Kondo M, Yamada K, Kitajima H, Yoshimori K, Sato K, Saito H, Aoe K, Tsuji T, Takiguchi Y, Takayama K, Komura N, Takiguchi T, Eguchi K (2018) Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia: Results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04). Cancer 124:606\u2013616. https:\/\/doi.org\/10.1002\/cncr.31128","journal-title":"Cancer"},{"key":"7576_CR14","doi-asserted-by":"publisher","first-page":"4294","DOI":"10.1002\/cncr.32406","volume":"125","author":"S Hamauchi","year":"2019","unstructured":"Hamauchi S, Furuse J, Takano T, Munemoto Y, Furuya K, Baba H, Takeuchi M, Choda Y, Higashiguchi T, Naito T, Muro K, Takayama K, Oyama S, Takiguchi T, Komura N, Tamura K (2019) A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in advanced gastrointestinal cancer patients with cancer cachexia. Cancer 125:4294\u20134302. https:\/\/doi.org\/10.1002\/cncr.32406","journal-title":"Cancer"},{"key":"7576_CR15","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/jcsm.12675","volume":"12","author":"H Wakabayashi","year":"2021","unstructured":"Wakabayashi H, Arai H, Inui A (2021) The regulatory approval of anamorelin for treatment of cachexia in patients with non-small cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer in Japan: facts and numbers. J Cachexia Sarcopenia Muscle 12:14\u201316. https:\/\/doi.org\/10.1002\/jcsm.12675","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"7576_CR16","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1023\/a:1015614505929","volume":"11","author":"T Matsumoto","year":"2002","unstructured":"Matsumoto T, Ohashi Y, Morita S, Kobayashi K, Shibuya M, Yamaji Y, Eguchi K, Fukuoka M, Nagao K, Nishiwaki Y, Niitani H (2002) The quality of life questionnaire for cancer patients treated with anticancer drugs (QOL-ACD): validity and reliability in Japanese patients with advanced non-small-cell lung cancer. Qual Life Res 11:483\u2013493. https:\/\/doi.org\/10.1023\/a:1015614505929","journal-title":"Qual Life Res"},{"key":"7576_CR17","first-page":"1001","volume":"85","author":"T Onodera","year":"1984","unstructured":"Onodera T, Goseki N, Kosaki G (1984) Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients. Nihon Geka Gakkai Zasshi 85:1001\u20131005","journal-title":"Nihon Geka Gakkai Zasshi"},{"key":"7576_CR18","first-page":"5","volume":"102","author":"R Zahorec","year":"2001","unstructured":"Zahorec R (2001) Ratio of neutrophil to lymphocyte counts\u2013rapid and simple parameter of systemic inflammation and stress in critically ill. Bratisl Lek Listy 102:5\u201314","journal-title":"Bratisl Lek Listy"},{"key":"7576_CR19","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.amjsurg.2007.12.057","volume":"197","author":"RA Smith","year":"2009","unstructured":"Smith RA, Bosonnet L, Raraty M, Sutton R, Neoptolemos JP, Campbell F, Ghaneh P (2009) Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma. Am J Surg 197:466\u2013472. https:\/\/doi.org\/10.1016\/j.amjsurg.2007.12.057","journal-title":"Am J Surg"},{"key":"7576_CR20","doi-asserted-by":"publisher","first-page":"e0138657","DOI":"10.1371\/journal.pone.0138657","volume":"10","author":"XL Xu","year":"2015","unstructured":"Xu XL, Yu HQ, Hu W, Song Q, Mao WM (2015) a novel inflammation-based prognostic score, the C-reactive protein\/albumin ratio predicts the prognosis of patients with operable esophageal squamous cell carcinoma. PLoS One 10:e0138657. https:\/\/doi.org\/10.1371\/journal.pone.0138657","journal-title":"PLoS One"},{"key":"7576_CR21","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/45230","volume":"402","author":"M Kojima","year":"1999","unstructured":"Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K (1999) Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402:656\u2013660. https:\/\/doi.org\/10.1038\/45230","journal-title":"Nature"},{"key":"7576_CR22","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1053\/j.gastro.2009.12.058","volume":"138","author":"S Adachi","year":"2010","unstructured":"Adachi S, Takiguchi S, Okada K, Yamamoto K, Yamasaki M, Miyata H, Nakajima K, Fujiwara Y, Hosoda H, Kangawa K, Mori M, Doki Y (2010) Effects of ghrelin administration after total gastrectomy: a prospective, randomized, placebo-controlled phase II study. Gastroenterology 138:1312\u20131320. https:\/\/doi.org\/10.1053\/j.gastro.2009.12.058","journal-title":"Gastroenterology"},{"key":"7576_CR23","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/jcsm.12351","volume":"10","author":"T Naito","year":"2019","unstructured":"Naito T, Mitsunaga S, Miura S, Tatematsu N, Inano T, Mouri T, Tsuji T, Higashiguchi T, Inui A, Okayama T, Yamaguchi T, Morikawa A, Mori N, Takahashi T, Strasser F, Omae K, Mori K, Takayama K (2019) Feasibility of early multimodal interventions for elderly patients with advanced pancreatic and non-small-cell lung cancer. J Cachexia Sarcopenia Muscle 10:73\u201383. https:\/\/doi.org\/10.1002\/jcsm.12351","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"7576_CR24","doi-asserted-by":"publisher","first-page":"111038","DOI":"10.1016\/j.mce.2020.111038","volume":"518","author":"R Sharma","year":"2020","unstructured":"Sharma R, Kopchick JJ, Puri V, Sharma VM (2020) Effect of growth hormone on insulin signaling. Mol Cell Endocrinol 518:111038. https:\/\/doi.org\/10.1016\/j.mce.2020.111038","journal-title":"Mol Cell Endocrinol"},{"key":"7576_CR25","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s13539-011-0051-5","volume":"3","author":"MA Honors","year":"2012","unstructured":"Honors MA, Kinzig KP (2012) The role of insulin resistance in the development of muscle wasting during cancer cachexia. J Cachexia Sarcopenia Muscle 3:5\u201311. https:\/\/doi.org\/10.1007\/s13539-011-0051-5","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"7576_CR26","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/s2468-1253(16)30106-6","volume":"1","author":"PA Hart","year":"2016","unstructured":"Hart PA, Bellin MD, Andersen DK, Bradley D, Cruz-Monserrate Z, Forsmark CE, Goodarzi MO, Habtezion A, Korc M, Kudva YC, Pandol SJ, Yadav D, Chari ST (2016) Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer. Lancet Gastroenterol Hepatol 1:226\u2013237. https:\/\/doi.org\/10.1016\/s2468-1253(16)30106-6","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"7576_CR27","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1111\/jgh.15792","volume":"37","author":"N Iwai","year":"2022","unstructured":"Iwai N, Sakagami J, Kagawa K (2022) Gastrointestinal: Acute pancreatitis related to a ghrelin receptor agonist. J Gastroenterol Hepatol 37:1473. https:\/\/doi.org\/10.1111\/jgh.15792","journal-title":"J Gastroenterol Hepatol"},{"key":"7576_CR28","doi-asserted-by":"publisher","first-page":"370","DOI":"10.4240\/wjgs.v7.i12.370","volume":"7","author":"B Nazha","year":"2015","unstructured":"Nazha B, Moussaly E, Zaarour M, Weerasinghe C, Azab B (2015) Hypoalbuminemia in colorectal cancer prognosis: nutritional marker or inflammatory surrogate? World J Gastrointest Surg 7:370\u2013377. https:\/\/doi.org\/10.4240\/wjgs.v7.i12.370","journal-title":"World J Gastrointest Surg"},{"key":"7576_CR29","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1515\/cclm.2008.089","volume":"46","author":"M Krzystek-Korpacka","year":"2008","unstructured":"Krzystek-Korpacka M, Matusiewicz M, Diakowska D, Grabowski K, Blachut K, Kustrzeba-Wojcicka I, Terlecki G, Gamian A (2008) Acute-phase response proteins are related to cachexia and accelerated angiogenesis in gastroesophageal cancers. Clin Chem Lab Med 46:359\u2013364. https:\/\/doi.org\/10.1515\/cclm.2008.089","journal-title":"Clin Chem Lab Med"},{"key":"7576_CR30","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1097\/j.pbj.0000000000000123","volume":"6","author":"P Tavares","year":"2021","unstructured":"Tavares P, Gon\u00e7alves DM, Santos LL, Ferreira R (2021) Revisiting the clinical usefulness of C-reactive protein in the set of cancer cachexia. Porto Biomed J 6:e123. https:\/\/doi.org\/10.1097\/j.pbj.0000000000000123","journal-title":"Porto Biomed J"},{"key":"7576_CR31","doi-asserted-by":"publisher","first-page":"dju124","DOI":"10.1093\/jnci\/dju124","volume":"106","author":"AJ Templeton","year":"2014","unstructured":"Templeton AJ, McNamara MG, \u0160eruga B, Vera-Badillo FE, Aneja P, Oca\u00f1a A, Leibowitz-Amit R, Sonpavde G, Knox JJ, Tran B, Tannock IF, Amir E (2014) Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst 106:dju124. https:\/\/doi.org\/10.1093\/jnci\/dju124","journal-title":"J Natl Cancer Inst"},{"key":"7576_CR32","doi-asserted-by":"publisher","first-page":"18758","DOI":"10.1038\/s41598-020-75745-8","volume":"10","author":"N Iwai","year":"2020","unstructured":"Iwai N, Okuda T, Sakagami J, Harada T, Ohara T, Taniguchi M, Sakai H, Oka K, Hara T, Tsuji T, Komaki T, Kagawa K, Yasuda H, Naito Y, Itoh Y (2020) Neutrophil to lymphocyte ratio predicts prognosis in unresectable pancreatic cancer. Sci Rep 10:18758. https:\/\/doi.org\/10.1038\/s41598-020-75745-8","journal-title":"Sci Rep"},{"key":"7576_CR33","doi-asserted-by":"publisher","first-page":"41298","DOI":"10.1038\/srep41298","volume":"7","author":"N Li","year":"2017","unstructured":"Li N, Tian GW, Wang Y, Zhang H, Wang ZH, Li G (2017) Prognostic role of the pretreatment C-reactive protein\/albumin ratio in solid cancers: a meta-analysis. Sci Rep 7:41298. https:\/\/doi.org\/10.1038\/srep41298","journal-title":"Sci Rep"},{"key":"7576_CR34","doi-asserted-by":"publisher","unstructured":"Burgassi F, Paillaud E, Poisson J, Bousquet G, Pamoukdjian F (2021) Prognostic value of prospective longitudinal CRP to albumin ratio among older outpatients with cancer. Cancers (Basel) 13. https:\/\/doi.org\/10.3390\/cancers13225782","DOI":"10.3390\/cancers13225782"},{"key":"7576_CR35","doi-asserted-by":"publisher","first-page":"7535","DOI":"10.1038\/s41598-020-64282-z","volume":"10","author":"T Barker","year":"2020","unstructured":"Barker T, Fulde G, Moulton B, Nadauld LD, Rhodes T (2020) An elevated neutrophil-to-lymphocyte ratio associates with weight loss and cachexia in cancer. Sci Rep 10:7535. https:\/\/doi.org\/10.1038\/s41598-020-64282-z","journal-title":"Sci Rep"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-023-07576-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-023-07576-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-023-07576-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T23:30:19Z","timestamp":1676331019000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-023-07576-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,14]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["7576"],"URL":"https:\/\/doi.org\/10.1007\/s00520-023-07576-y","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,14]]},"assertion":[{"value":"12 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Takeshi Ishikawa and Toshifumi Tsuji received honoraria from Ono Pharmaceutical Co., Ltd. The company had no role in the study design; in the data collection, analysis, or interpretation; or in writing the draft.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study complied with the Declaration of Helsinki and was approved by the Ethics Committees of Fukuchiyama City Hospital (approval number: 3\u201366).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all patients by the opt-out method.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"115"}}